Detailed company information
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Feb 25, 2026
Earnings Transcript for 2025 - Q3Released: Nov 05, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Feb 26, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 02, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Nov 02, 2023
Earnings Transcript for 2023 - Q2Released: Aug 03, 2023
Earnings Transcript for 2023 - Q1Released: May 11, 2023
Earnings Transcript for 2022 - Q4Released: Mar 16, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 11, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Mar 10, 2022
Earnings Transcript for 2021 - Q2Released: Aug 16, 2021
Earnings Transcript for 2021 - Q1Released: May 10, 2021
Earnings Transcript for 2020 - Q4Released: Mar 11, 2021
Earnings Transcript for 2020 - Q3Released: Nov 05, 2020
Earnings Transcript for 2020 - Q2Released: Aug 06, 2020
Geron's Q1 2026 demand trend shows stable early momentum with a focus on expanding prescribing accounts and patient volume to drive significant back-half revenue growth. The company's strategic commercial efforts aim to sustain demand growth through targeted community-based programs and disciplined financial guidance.
Read post
Dafinchi
